Fair point, docj. I bring the science forward because for investors, understanding where CCR5 fits into oncology, inflammation, and other disease states is exactly what informs valuation down the road.

For me it’s not about debating endlessly — it’s about separating noise from the signal that will actually drive shareholder value once recognition and partnerships catch up.